4 completed, 4 unknown, 1 suspended, 1 terminated. 11 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 4, Unknown 4, Suspended 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Unknown 2 |
| Phase 3 | 1 | Completed 1 |
Follow EGCG: new trials by email Literature Review of EGCG trials Research Report on EGCG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reducing Frailty for Older Cancer Survivors Using Supplements II Epigallocatechin-3-Gallate (EGCG), Microcrystalline cellulose (MCC), Ascorbic Acid (Vitamin C) - Frailty, Inflammation | Phase 2 | Suspended | University of Rochester | 118 | 2024-10-25 | 2026-06-26 |
| Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary Pneumonia EGCG - Pneumonia, Interstitial, Cancer Patients | Phase 2 | Completed | Shandong Cancer Hospital and Institute | 111 | 2023-06-05 | 2025-11-28 |
| Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients EGCG - Interstitial Pneumonia, Neoplasms Malignant | Phase 1 / Phase 2 | Unknown | Shandong Cancer Hospital and Institute | 78 | 2023-01-05 | 2023-05-30 |
| Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy EGCG, mLDG - Lung Neoplasms, Esophagitis | Phase 2 | Unknown | Shandong Cancer Hospital and Institute | 83 | 2015-04-01 | 2020-04-28 |
| Effect of Epigallocatechin -3-gallate Supplementation in Traumatic Brain Injury Patients EGCG, Placebo (deionized water) - Traumatic Brain Injury | Phase 2 / Phase 3 | Completed | National Nutrition and Food Technology Institute | 30 | 2015-03-01 | 2016-06-07 |
| Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant Radiotherapy EGCG, placebo - Breast Neoplasms, Dermatitis | Phase 2 | Unknown | Shandong Cancer Hospital and Institute | 68 | 2014-12-01 | 2019-04-05 |
| "Using Epigallocatechin Gallate (EGCG) and Cognitive Training to Modulate Cognitive Performance in Patients With Fragile X Syndrome" (TESFX) EGCG, Placebo, Cognitive training - Fragile X Syndrome | Phase 2 | Completed | Parc de Salut Mar | 44 | 2013-06-11 | 2019-05-10 |
| A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL) Epigallocatechin-3-gallate (EGCG), Placebo - Light Chain (AL) Amyloidosis, Cardiac Involvement | Phase 2 | Completed | Florian Michel | 38 | 2013-04-01 | 2017-10-17 |
| Study of Topically Applied Green Tea Extract for Radio Dermatitis and Radiation Mucositis EGCG - Epigallocatechin Gallate, Radio Dermatitis | Phase 1 / Phase 2 | Unknown | Shandong Cancer Hospital and Institute | 15 | 2011-09-01 | 2020-04-28 |
| Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II Polyphenon E, Placebo - Multiple Sclerosis | Phase 2 | Terminated | Louisiana State University Health Sciences Center in New Orleans | 11 | 2011-07-01 | 2014-03-14 |
| Effect of EGCG on the Body's Response to Insulin EGCG - Hypertension, Obesity | Phase 2 | Withdrawn | University of Maryland, Baltimore | 2007-02-01 | 2022-03-04 |
Inflammation (2) · Lung Diseases, Interstitial (2) · Amyloidosis (1) · Brain Injuries, Traumatic (1) · Breast Neoplasms (1) · Dermatitis (1) · Diabetes Mellitus, Type 2 (1) · Esophagitis (1) · Fragile X Syndrome (1) · Frailty (1) · Hypertension (1) · Insulin Resistance (1) · Lung Neoplasms (1) · Multiple Sclerosis (1) · Neoplasms (1)
Shandong Cancer Hospital and Institute (5) · Florian Michel (1) · Louisiana State University Health Sciences Center in New Orleans (1) · National Nutrition and Food Technology Institute (1) · Parc de Salut Mar (1) · University of Maryland, Baltimore (1) · University of Rochester (1)
United States (3) · China (2) · Germany (1) · Iran (1) · Spain (1)
Ligang Xing, MD,PhD (2) · Jesus F Lovera, MD (1) · Jinming Yu, M.D. (1) · Kashif Munir, MD (1) · Ligang Xing, MD, PhD (1) · Rafael de la Torre, PhamD (1) · Xing Ligang, MD,PhD (1)
PMID 24444526, PMID 26298797, PMID 35648426, PMID 37620508, PMID 38632501, PMID 41549240
K23AT004433 (1)